Vivos Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.39M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | Apr 15, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 19, 2025 | After market close | $6.80M | $-0.49 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 20, 2025 | After market close | $3.80M | $-0.55 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | $3.00M | $-0.45 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $3.90M | $-0.40 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | After market close | $4.10M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | $3.40M | $-1.63 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 29, 2024 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 16, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | Jun 8, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 30, 2023 | After market close | – | – | – |
Press releases
Announcements Vivos Therapeutics filed with the SEC
Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Other events · EX-99.1 to Form 8-K
Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support
Material agreement · New financial obligation · Listing notice · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Reports Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Other events · EX-99.1 to Form 8-K
Therapeutics Reports Significant Revenue Growth
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Other events · EX-99.1 to Form 8-K
PRABHU, LATA K. SHETE, M.D.s
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K/A
PRABHU, LATA K. SHETE, M.D.s
Acquisition or disposition completed · Other events · EX-99.2 to Form 8-K/A
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Acquisition or disposition completed · Other events · EX-99.3 to Form 8-K/A
Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Completes Acquisition of The Sleep Center of Nevada
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Other events · EX-99.1 to Form 8-K
Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Additional Strategic Initiatives Aimed at Accelerating Anticipated Timeline for Cash Flow Positive Operations
Auditor change · Other events · EX-99.1 to Form 8-K
Therapeutics Reports Fourth Quarter and Full Year 2022
Results of operations · EX-99.1 to Form 8-K
Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from
Other events · EX-99.1 to Form 8-K
Vivos Therapeutics Announces Pricing of $8 Million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Reports Second and Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Therapeutics Provides Update on Revenue Recognition Review
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
Therapeutics Announces Multiple Regulatory Clearances in Australia for its Entire Line of Oral Appliances
Other events · EX-99.1 to Form 8-K
Therapeutics’ SLEEP 2022 Annual Meeting Presentation
Other events · EX-99.1 to Form 8-K
Therapeutics Reports First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Fourth Quarter and Full Year 2021
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K